---
figid: PMC5507646__onco12134-fig-0001
figlink: /pmc/articles/PMC5507646/figure/onco12134-fig-0001/
number: F1
caption: 'BRAF mutations in the context of mitogen‐activated protein kinase (MAPK)
  molecular alterations. The approximate observed frequencies of common driver mutations
  in the MAPK pathway in lung cancer are shown on the left of the figure. BRAF valine
  at codon 600 (V600E) mutations leading to constitutive activation of BRAF are relatively
  rare, occurring in 1%–2% of lung cancers. For patients with activating BRAF mutations,
  direct inhibition of BRAF alone or in combination with downstream MEK inhibition
  is currently under clinical evaluation. Notable BRAF and MEK inhibitors under development
  are depicted on the right.Abbreviations: BRAF, B‐Raf proto‐oncogene, serine/threonine
  kinase; EGFR, epidermal growth factor receptor; ERK, extracellular signal‐regulated
  kinase; HER2, human epidermal growth factor receptor 2; KRAS, KRAS proto‐oncogene,
  GTPase; MEK, mitogen‐activated protein kinase kinase; MET, MET proto‐oncogene, receptor
  tyrosine kinase; NRAS, NRAS proto‐oncogene, GTPase; ROS, ROS proto‐oncogene 1, receptor
  tyrosine kinase.'
pmcid: PMC5507646
papertitle: 'Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling
  to Rationally Designed Therapy.'
reftext: Christina S. Baik, et al. Oncologist. 2017 Jul;22(7):786-796.
pmc_ranked_result_index: '132064'
pathway_score: 0.9410593
filename: onco12134-fig-0001.jpg
figtitle: BRAF mutations in the context of mitogen‐activated protein kinase (MAPK)
  molecular alterations
year: '2017'
organisms: Homo sapiens
ndex: 4c0e5dc3-df02-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5507646__onco12134-fig-0001.html
  '@type': Dataset
  description: 'BRAF mutations in the context of mitogen‐activated protein kinase
    (MAPK) molecular alterations. The approximate observed frequencies of common driver
    mutations in the MAPK pathway in lung cancer are shown on the left of the figure.
    BRAF valine at codon 600 (V600E) mutations leading to constitutive activation
    of BRAF are relatively rare, occurring in 1%–2% of lung cancers. For patients
    with activating BRAF mutations, direct inhibition of BRAF alone or in combination
    with downstream MEK inhibition is currently under clinical evaluation. Notable
    BRAF and MEK inhibitors under development are depicted on the right.Abbreviations:
    BRAF, B‐Raf proto‐oncogene, serine/threonine kinase; EGFR, epidermal growth factor
    receptor; ERK, extracellular signal‐regulated kinase; HER2, human epidermal growth
    factor receptor 2; KRAS, KRAS proto‐oncogene, GTPase; MEK, mitogen‐activated protein
    kinase kinase; MET, MET proto‐oncogene, receptor tyrosine kinase; NRAS, NRAS proto‐oncogene,
    GTPase; ROS, ROS proto‐oncogene 1, receptor tyrosine kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GZMM
  - MAPK1
  - MAPK3
  - EGFR
  - MAP2K1
  - MET
  - NRAS
  - BRAF
  - ERBB2
  - KRAS
  - HRAS
  - MAP2K2
  - ROS1
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Binimetinib
  - tyrosine
  - Cancer
  - Lung cancer
genes:
- word: MET:<1%
  symbol: MET1
  source: hgnc_alias_symbol
  hgnc_symbol: GZMM
  entrez: '3004'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: 'MEK1:'
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: 'MET:'
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: 'NRAS:'
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: 'HER2:'
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: 'KRAS:'
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: 'ROS1:'
  symbol: ROS1
  source: hgnc_symbol
  hgnc_symbol: ROS1
  entrez: '6098'
chemicals:
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Binimetinib
  source: MESH
  identifier: C581313
- word: tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC5507646__F1
redirect_from: /figures/PMC5507646__F1
figtype: Figure
---
